Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty

Merkhof, Lambert F.M. van den; Zijlstra, Felix; Olsson, Hans; Grip, Lars; Veen, Gerrit; Bär, Frits W.; Brand, Moshe; Simoons, Maarten L.; Verheugt, Freek W.A.

doi:10.1016/s0735-1097(99)00038-8

Cited by 126 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 The early use of glycoprotein IIb ⁄ IIIa inhibitors can induce reperfusion before primary PCI for acute STEMI. 26 The combination of a glycoprotein IIb ⁄ IIIa inhibitor plus heparin significantly reduces the intracoronary thrombus burden of the culprit lesions, improves the perfusion grade, and decreases the severity of the obstruction in patients with unstable angina or non-Q-wave MI. 27 We speculated that the association between use of glycoprotein IIb ⁄ IIIa inhibitors and shorter door-to-balloon time might originate from the facilitation in the clot dissolution, thereby hastening the passage of guide wires through the culprit lesions during PCI.…”

Section: Discussionmentioning

confidence: 99%

Impact of an Audit Program and Other Factors on Door‐to‐balloon Times in Acute ST‐elevation Myocardial Infarction Patients Destined for Primary Coronary Intervention

Lai

Fan

Liao

et al. 2009

Academic Emergency Medicine

View full text Add to dashboard Cite

Objectives: This before-after study investigated the association between an audit program and door-toballoon times in patients with acute ST-elevation myocardial infarction (STEMI) and explored other factors associated with the door-to-balloon time.Methods: An audit program that collected time data for essential time intervals in acute STEMI was developed with data feedback to both the Department of Emergency Medicine and the Department of Cardiology. The door-to-balloon times for 76 consecutive acute STEMI patients were collected from February 16, 2007, through October 31, 2007, after the implementation of the audit program, as the intervention group. The control group was defined by 104 consecutive acute STEMI patients presenting from April 1, 2006, through February 15, 2007, before the audit was applied. A multivariate linear regression model was used for analysis of factors associated with the door-to-balloon time.Results: The geometric mean 95% CI of the door-to-balloon time decreased from 164.9 (150.3, 180.9) minutes to 141.9 (127.4, 158.2) minutes (p = 0.039) in the intervention phase. The median door-to-balloon time was 147.5 minutes in the control group and 136.0 minutes in the intervention group (p = 0.09). In the multivariate regression model, the audit program was associated with a shortening of the door-toballoon time by 35.5 minutes (160.4 minutes vs. 195.9 minutes, p = 0.004); female gender was associated with a mean delay of 58.4 minutes (208.9 minutes vs. 150.5 minutes; p = 0.001); posterolateral wall infarction was associated with a mean delay of 70.5 minutes compared to anterior wall infarction (215.4 minutes vs. 144.9 minutes; p = 0.037) and a mean delay of 69.5 minutes compared to inferior wall infarction (215.4 minutes vs. 145.9 minutes; p = 0.044). The use of a glycoprotein IIb ⁄ IIIa inhibitor was associated with a 46.1 minutes mean shortening of door-to-balloon time (155.7 minutes vs. 201.8 minutes; p < 0.001). Conclusions:The implementation of an audit program was associated with a significant reduction in door-to-balloon times among patients with acute STEMI. In addition, female patients, posterolateral wall infarction territory, and nonuse of glycoprotein IIb ⁄ IIIa inhibitor were associated with longer door-toballoon times.ACADEMIC EMERGENCY MEDICINE 2009; 16:333-342 ª

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of an Audit Program and Other Factors on Door‐to‐balloon Times in Acute ST‐elevation Myocardial Infarction Patients Destined for Primary Coronary Intervention

Lai

Fan

Liao

et al. 2009

Academic Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…Essas limitações têm levado a uma procura constante da terapia de reperfusão ideal, ou seja, que possa oferecer rapidamente fluxo TIMI grau 3. [255][256][257] demonstraram que a combinação de baixas doses do ativador de plasminogênio (alteplase ou retepelase) mais abciximab oferece reperfusão miocárdica mais rápida e mais completa, levando-se em conta o grau de fluxo TIMI aos 60 e 90min.…”

Section: Combinações Farmacológicas -unclassified

“…Outra classe de agentes farmacológicos, os inibidores da glicoproteína IIb/IIIa, potente bloqueador da via final da adesão plaquetária, também já foi testada em estudos e séries menores. A seu favor, exibe perfil de risco menor, pois não promove a ocorrência de acidente vascular cerebral hemorrágico ou outros sangramentos maiores, mas cursa com cifra de patência arterial (fluxo TIMI grau 3) menor, de cerca de 35%, em média 255,257,265,[472][473][474][475] .…”

Section: Intervenção Coronariana Percutânea Facilitada -unclassified

III Diretriz sobre tratamento do infarto agudo do miocárdio

Avezum¹,

Carvalho²,

Mansur³

et al. 2004

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Classe I: evidência ou concordância geral de que o tratamento é benéfico, útil e eficaz.Classe II: evidência conflitante e/ou divergência de opinião quanto à utilidade e à eficácia do tratamento.Classe IIa: forças das evidências/opiniões em favor da utilidade e da eficácia.Classe IIb: forças das evidências/opiniões menos bem estabelecidas quanto à utilidade e à eficácia.Classe III: evidência ou concordância geral de que o tratamento não é útil/eficaz e em alguns casos pode ser prejudicial. Nível de evidência A: presença de múltiplos estudos clínicos randomizados.Nível de evidência B: presença de um único estudo clínico randomizado ou de estudos não-randomizados.Nível de evidência C: consenso de especialistas.O nível de evidência será apresentado apenas para os tratamentos do infarto do miocárdio, não se aplicando aos procedimentos diagnósticos. Todos os métodos complementares deverão ser realizados por profissionais experientes, segundo as recomendações específicas de cada especialidade.

show abstract

“…Angiographic studies in patients with acute myocardial infarction have demonstrated that abciximab in addition to aspirin and adjusted-dose heparin reopens about 40-50% of thrombosed coronaries to Thrombolysis in Myocardial Infarction (TIMI) flow grades II or III [27,28].The mechanism of revascularisation is unknown.…”

Section: Rationale For Abciximabmentioning

confidence: 99%

Abciximab in acute stroke

Baumgartner¹

2004

Swiss Arch Neurol Psychiatr

View full text Add to dashboard Cite

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty

Cited by 126 publications

References 20 publications

Impact of an Audit Program and Other Factors on Door‐to‐balloon Times in Acute ST‐elevation Myocardial Infarction Patients Destined for Primary Coronary Intervention

Impact of an Audit Program and Other Factors on Door‐to‐balloon Times in Acute ST‐elevation Myocardial Infarction Patients Destined for Primary Coronary Intervention

III Diretriz sobre tratamento do infarto agudo do miocárdio

Abciximab in acute stroke

Contact Info

Product

Resources

About